Please assess the completion status of the following clinical trial:

Trial Title: Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age and has successfully completed Keryx Study 101-301.~* Diagnosis of DM2 based on ADA criteria.~* Continued stable seated systolic blood pressure \< 150 mmHg and diastolic blood pressure \< 90 mmHg.~* Provide written informed consent to participate in the study.~* If female and of childbearing potential, must continue to be willing to use adequate contraception, as determined by the investigator, for the duration of the study.~Exclusion Criteria:~* Evidence of hepatic dysfunction including total bilirubin \> 2.0 mg/dL (34 micromol/L) or liver enzymes \> 3 times upper limit of normal.~* Unstable angina pectoris or New York Heart Association Class III or IV congestive heart failure.~* A history of any major medical condition, including but not limited to: aortic aneurysm; myocardial infarction, stroke, or other cardiovascular events in the past 3 months; gastrointestinal bleeding in the past 3 months; HIV; and other medical conditions deemed serious by the investigator. Active Hepatitis B or C (currently active disease defined as an abnormal liver biopsy or persistent, elevated transaminases, SGOT, SGPT).~* Any risk of bleeding, including a history of bleeding diathesis and a platelet count \< 100,000/mm³.~* Active or metastatic cancer (note: superficial basal carcinoma of the skin is not an exclusion).~* Anticipated surgery within trial period.~* History of noncompliance to medical regimens in Keryx Study No.101-301.~* Participation in any experimental drug study in the past 60 days, except for KRX-101-301, prior to entry into the study, or plan to participate in any experimental drug study during the study period.~* Lactation, pregnancy, or an anticipated or planned pregnancy during the study period.~* Known allergy or intolerance to any heparin-like compounds.~* Patients with other specific renal diseases known to be the cause of nephropathy, and patients with other specific, clinically significant renal disease.~* Inability to give an informed consent or cooperate with the study personnel.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sulodexide (Type: EXPERIMENTAL): Open label extension to original trial

Based on this trial design, predict the completion outcome and termination type (if applicable).